Testing a New mRNA Cancer Treatment for Advanced Solid Tumors
Part of Cancer clinical trials.
This early-stage trial tests a new mRNA-based drug designed to help your immune system fight advanced cancers that haven't responded to standard treatments. The study measures safety, tolerability, and whether it can slow or shrink your tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced cancer (spread or come back) that did not respond to at least two lines of prior treatment, with no other standard options available
- Your overall health is good enough to tolerate treatment (ECOG score 0–1, meaning you can do most daily activities)
- You are expected to live at least 3 months
- At least 4 weeks have passed since your last chemotherapy, radiotherapy, or surgery
- Your blood counts, liver, and kidney function are adequate; your heart pumps well (ejection fraction ≥50%)
- You have no uncontrolled heart disease, active infections (including HIV, hepatitis, or tuberculosis), or active autoimmune diseases
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, IL-22BP/LNP, for people with advanced solid tumors (like soft tissue sarcoma, head and neck cancer, melanoma) that have worsened after standard treatments. The main goals are to see if the drug is safe and tolerable, and to learn if it might help shrink or slow the cancer.
This early-stage trial tests a new drug that combines a peptide with genetic material (siRNA) designed to help your immune system fight advanced cancers that haven't responded to standard treatments. Researchers want to see if it's safe and whether it can shrink tumors.
This Phase 1 trial tests a new drug called IUAb190708 designed to help your immune system fight advanced or recurrent solid cancers. The study will evaluate its safety, how your body handles it, and whether it works against your tumor.
This early-stage trial tests a new medicine called NCP-IL-22BP mRNA, given as an injection, to see if it is safe and well-tolerated in patients with advanced cancers that have not responded to standard treatments. The medicine is designed to boost your immune system to fight cancer cells.
This trial tests a personalized mRNA cancer vaccine (RH125) for people with advanced solid tumors that have spread or cannot be removed by surgery. It may be an option if standard treatments have stopped working or are not suitable, and for some, it will be given with a PD-1 blocker.
This Phase 1/2 study tests an mRNA vaccine (mRNA-4359) either alone or combined with an immune checkpoint antibody (immunotherapy). It’s for people with advanced solid tumors to see if it can shrink tumors and how safe it is.
Hear when a new Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.